Skip to main content
 

Simon Jackson
Click to enlarge

Simon Jackson

 Director

Email:

Trained in physics and molecular biology at Cambridge and Harvard, Simon has spent 25 years in technology commercialisation and finance. At Rapid Innovation for the last 9 years, Simon has worked with companies in the areas of sensor technologies, alternative energy generation and agricultural biotech. He also works with companies across RIG’s client portfolio on challenges associated with investor readiness and fundraising. He has a special interest in helping RIG clients enter the Chinese market.

Previously, he was a director at a niche private equity company for 12 years where he invested in a range of technology-related businesses, in parallel with which he conducted international M&A and fundraising for technology-related businesses.

Simon has an MBA from INSEAD and speaks French, Chinese and Italian. He is a keen jazz pianist.

A new atmosphere: reflections on holding concerts and winning clients in the time of COVID-19

For over 5 years, I have been hosting ‘house concerts’ where touring international musicians play a private gig in my flat to an audience of friends and friends of friends. The gigs are intimate affairs -both for the physical proximity, and because there can be lots of interaction. And sometimes there’s a level of connection between artist and audience such that at the end of the evening, everyone feels that something very special happened.

Read more
 

BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology

RIG client Akribion Therapeutics is progressing the development of the CRISPR-Cas9 technology, with initial applications in oncology 

Read more
 

SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal

RIG client SolasCure has published further data to support the use of their enzymatic debridement product to accelerate wound healing 

Read more
 
 
 
  Back to list